Diagnostics; making a difference

Member Press Releases

Current Articles | Categories | Search | Syndication

29 July 2016  
BBI Solutions extends its antibodies range
By @ 11:07 :: 56 Views


BBI Solutions (BBI) has vastly increased its antibodies range across a wide variety of disease areas including bone metabolism, cardiac, growth factors, thyroid, and sepsis. This range extension has been in response to growing demand in the IVD market. 

Read More

28 July 2016  
Trading Update and Notice of Results
By @ 10:30 :: 54 Views


The Company is pleased to provide a trading update for the six months ending 30th June 2016.  

Read More

25 July 2016  
Cytox launches breakthrough genetic biomarker research assay for Alzheimer’s disease
By @ 11:52 :: 59 Views


Simple blood-based test will help reduce screening failure in clinical trials and assist drug discovery
Read More

25 July 2016  
Cytox launches interpretive software for breakthrough genetic biomarker research assay for Alzheimer’s risk assessment at AAIC
By @ 11:45 :: 59 Views


Combination will identify amyloid-positive subjects more efficiently and help reduce screening
failure rates in clinical trials
Read More

11 July 2016  
BBI Solutions new SCIPAC Clinical Specimen Panels, speeding up assay development for infectious diseases
By @ 13:26 :: 103 Views


BBI Solutions (BBI) today announced the launch of SCIPAC Clinical Specimen Panels. SCIPAC are quantitative panels of clinical specimen, collected from multiple donors of known genotype. 

Read More

11 July 2016  
Export Award Winner Attending AACC
By @ 09:15 :: 86 Views


BBI Solutions (BBI), recent winners of the Made in the UK Export Award, will be attending the AACC Clinical Lab Expo in Philadelphia next month. 

Read More

07 July 2016  
National Institute for Health and Care Excellence backs blood test for liver disease
By @ 16:20 :: 99 Views

·    Organisation recommends simple blood test for diagnosing liver fibrosis in people with Non Alcoholic Fatty Liver Disease (NAFLD)

·    An estimated 14 to 27 percent of the general population in the industrialised world has NAFLD1, which is often caused by obesity

·    The ADVIA Centaur ELF Test is an easy, standardised, accurate, minimally-invasive blood test that measures liver damage, also known as fibrosis

·    The ELF test is convenient to request compared to biopsy and/or scan, since it requires only a routine blood sample with test results available within an hour

Read More

28 June 2016  
SEBIA, SPECIALIST IN ELECTROPHORESIS WILL DISTRIBUTE WORLDWIDE SERALITE®– FLC SERUM LATERAL FLOW IMMUNOASSAYS FOR THE DIAGNOSIS AND MONITORING OF MULTIPLE MYELOMA
By @ 09:38 :: 122 Views

Paris, France, and York, UK, June 27, 2016 – Sebia, the world leader in medical diagnostics by electrophoresis, and Abingdon Health, an in-vitro diagnostic group, today announce that they have entered into a multi-year, exclusive, global distribution agreement. The deal allows Sebia to add Abingdon Health’s Seralite®– FLC Dual Kappa and Lambda serum lateral flow immunoassay to its worldwide offering. The financial terms of the agreement have not been disclosed.
Read More

24 June 2016  
AGM Statement and Result of AGM
By @ 14:08 :: 118 Views

 

24 June 2016

 

At the AGM held earlier today it was announced that revenues from the core biomarker services activities remained buoyant in the first half with a strong order book, including repeat business, and a developing pipeline. TMT revenue growth has continued into 2016 and TMT was highly visible at the recent meeting of the American Society for Mass Spectrometry. The growing recognition of tau as a therapeutic target in Alzheimer’s disease should increase interest in new treatments which could favourably affect our compounds targeting CK1d in the tau pathway. We are confident that the business remains on track in 2016 to deliver a significant increase in revenues.

Read More

22 June 2016  
Increased efficiency and faster viral load results with DxN VERIS Molecular Diagnostics System
By @ 09:16 :: 112 Views

Niguarda Hospital, Milan, shares experiences in newly available case study

 

Nyon, Switzerland — (21 June 2016)A newly released case study, available from Beckman Coulter, describes the experiences of Niguarda Hospital’s Molecular Biology Laboratory in the assessment of the DxN VERIS Molecular Diagnostics System.  Involving fewer steps and reagents, and with true, single sample random access, DxN VERIS increased laboratory efficiency and allowed faster turnaround of viral load results.

Read More

Previous Page | Next Page